Form 4: Paula K. Cobb Acquires 15,000 Stock Options in Prothena Corp Public Ltd Co

Director Paula K. Cobb acquired 15,000 stock options in Prothena Corp Public Ltd Co on May 15, 2024, exercisable at $22.39.

Summary

• On May 15, 2024, Paula K. Cobb, a director of Prothena Corp Public Ltd Co, acquired 15,000 stock options.
• The exercise price for these options is $22.39.
• The options vest on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2025, assuming continuous service as a director.
• The options expire on May 15, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction of stock options being granted to a director. It doesn't inherently indicate positive or negative implications for the company's performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology industry, where stock options are commonly used to incentivize and align the interests of directors and management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their directors and officers.
• The vesting schedule and exercise price are generally aligned with industry norms, aiming to reward long-term value creation.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, incentivizing value creation.
• Employees are not directly impacted by this transaction.

Key Dates